Does Medtronic Belong in Your Portfolio?

NYSE: MDT | Medtronic plc. Ordinary Shares News, Ratings, and Charts

MDT – Medtronic (MDT), an established provider in the medical devices sector, has been improving its financials of late. As U.S. hospitals are now, finally, able to begin shifting their focus (and caregiving) away from COVID-19 and back to other diseases and regular, profitable, surgeries, we believe MDT is strategically positioned to generate healthy returns in the upcoming months. Read on for some details.

Based in Ireland, Medtronic plc. (MDT) is one of the largest producers of medical devices in the world. The company is known for its product innovations in the Cardiac and Vascular Group segment, Minimally Invasive Technologies Group segment, Restorative Therapies Group and Diabetes Group segments. Earlier this month, the company was named to Fortune’s 2021 World’s Most Admired Companies List. In Fortune’s  Medical Products and Equipment industry, MDT is ranked #4.

The company has been witnessing revenue growth lately based on rising surgical procedures that were deferred last year due to the COVID-19 pandemic.

The stock has gained 17.3% over the past six months to close Friday’s trading session at $119.74 after hitting its 52-week high of $119.88.

We expect MDT  to keep soaring based on the following factors:

Subsiding COVID-19 Risks

MDT was hard hit by the COVID-19  pandemic as patients deferred surgical procedures and limited their visit to  hospitals. However, as  COVID-19 risks are gradually subsiding, hospitals are witnessing a resumption in demand for regular surgeries.

According to an  analysis by Emergen Research, the global medical device connectivity market is expected to reach a value of $6.36 billion by 2027, growing at a CAGR of 24.3%. With this,  MDT is expected to witness significant growth going forward.

Sequential Growth Across All Segments

The company’s worldwide revenue increased 17.5% sequentially to $7.65 billion for the fiscal 2021 second quarter, ended October 30, 2020. Its revenue from its Cardiac & Vascular Group increased 12% sequentially, while its revenue from its Restorative Therapies Group increased 20.5% sequentially over the same period. Its revenue from its Minimally Invasive Therapies Group was reported to be $2.29 billion, representing a  6.7% year-over-year increase, and its Diabetes Group’s revenue increased 2.1% sequentially. Its non-GAAP EPS increased 64.5% sequentially to $1.02.

FDA Approvals

In January, MDT U.S. Food and Drug Administration (FDA) approval for its  DiamondTemp Ablation (DTA) system. The system  treats patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy. The DiamondTemp system is the first FDA-approved, temperature-controlled, irrigated radiofrequency (RF) ablation system with diamonds currently available to deliver ablations.

The FDA also cleared the use of the company’s Midas Rex high speed drills, which further strengthens MDT’s leadership in  navigated robotic spine surgery. In October 2020, the FDA approved the company’s Abre venous self-expanding stent system.

Favorable Analyst Outlook

Analysts expect the company’s revenue to increase 35.2% for the quarter ending April 31, 2021, 3.5% in 2021 and 8.6% in 2022. Its EPS is expected to grow 146.6% for the quarter ending April 31, 2021, 38.8% in 2022 and at a rate of 10.3% per annum over the next five years.

Wall Street analysts expect the stock to reach $129.29 in the near term, which represents  a potential 8.9% upside.

POWR Ratings are in Favor

MDT has an overall rating of B, which equates to Buy in our POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors with each factor weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight different categories. Among these categories, MDT has a B grade for Sentiment. This is consistent with analysts’ expectations that the company will generate significant revenue and EPS in the upcoming months.

Moreover, the stock also has a B grade for Stability. The stock is also rated for Growth, Value, Momentum and Quality. Click here to get all of MDT’s ratings.

The stock is ranked #51 of 181 stocks in the C-rated Medical – Devices & Equipment industry.

Click here to access several other top-rated stocks in the same industry.

Bottom Line

MDT is strategically positioned to generate significant returns in the near term. The company is focused on geographical diversification of its business and product innovation. At a trailing-12-month p/s ratio of 5.77x (versus the industry average 9.04x), we think it wise to bet on the stock now because  it has plenty of upside.

Want More Great Investing Ideas?

“MUST OWN” Growth Stocks for 2021

4,000 or Bust for S&P 500!

7 Best ETFs for the NEXT Bull Market

5 WINNING Stocks Chart Patterns

 


MDT shares were unchanged in after-hours trading Tuesday. Year-to-date, MDT has gained 2.17%, versus a 4.93% rise in the benchmark S&P 500 index during the same period.


About the Author: Manisha Chatterjee


Since she was young, Manisha has had a strong interest in the stock market. She majored in Economics in college and has a passion for writing, which has led to her career as a research analyst. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
MDTGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

A Case of Stock Market Whiplash

Just when the stock market (SPY) was inches away from a record high at 4,000 it got saddled with 6 days of downward pressure. Why did this happen? Is the pain over? What happens next? Read on below for answers …

:  |  News, Ratings, and Charts

2 Renewable Energy Stocks to Add to Your Watchlist

The clean energy industry is witnessing an unprecedented rally, with governments worldwide investing heavily to reduce their nations’ carbon footprints. Companies including Hubbell (HUBB) and Hallador Energy (HNRG) have been capitalizing on this trend and have delivered solid returns over the past year. Driven by federal subsidies and a rising awareness-driven demand for clean energy products, we think both names should keep climbing in the upcoming months.

:  |  News, Ratings, and Charts

Why I Believe Gold Will Rally, and 3 Stocks That Stand to Benefit the Most

While treasuries and tech stocks bounced back, the rest of market continued its decline Friday. David Cohne sees inflation as a major risk for investors and believes that gold will start a new rally. This should benefit mining stocks such as Gold Corporation (GOLD), Newmont Corp. (NEM), and Kinross Gold Corporation (KGC).

:  |  News, Ratings, and Charts

Cybersecurity Industry in 2021: The Complete Investors Guide

The cybersecurity industry expects to see tremendous growth in the next decade. Therefore investors should consider adding McAfee Corp. (MCFE), Radware Ltd. (RDWR), Qualys Inc. (QLYS), Proofpoint Inc. (PFPT), and Norton Lifelock Inc. (NLOK) to their portfolios.

:  |  News, Ratings, and Charts

Why I Believe Gold Will Rally, and 3 Stocks That Stand to Benefit the Most

While treasuries and tech stocks bounced back, the rest of market continued its decline Friday. David Cohne sees inflation as a major risk for investors and believes that gold will start a new rally. This should benefit mining stocks such as Gold Corporation (GOLD), Newmont Corp. (NEM), and Kinross Gold Corporation (KGC).

Read More Stories

More Medtronic plc. Ordinary Shares (MDT) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All MDT News